BioMarin remains a top mid-cap pick, says Cowen Cowen said BioMarin remains a top mid-cap pick following Q3 results. The firm noted a large Naglazyme order which was pushed into Q4 but believes underlying demand trends remain solid. Cowen also sees a reacceleration in revenue growth in 2014 with the launch of its Vimizim product. Shares are Outperform rated with an $85 price target.
News For BMRN From The Last 14 Days
Check below for free stories on BMRN the last two weeks.
Deutsche Bank to host a conference BioFest is being held in Boston on December 2-3 with webcasted company presentations to begin on December 3 at 7:50 am; not all company presentations may be webcasted. Webcast Link